<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Bridgebio Oncology Therapeutics, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc</link>
    <description>Latest news and press releases for Bridgebio Oncology Therapeutics, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 20:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/bridgebio-oncology-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7392551cc36e47532f1a1.webp</url>
      <title>Bridgebio Oncology Therapeutics, Inc.</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc</link>
    </image>
    <item>
      <title>BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-presents-preclinical-data-demonstrating-pan-kras-inhibitor-bbo-11818-has-robust-anti-tumor-activity-in-kras-mutant-preclinical-models-at-the-aacr-annual-meeting-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-presents-preclinical-data-demonstrating-pan-kras-inhibitor-bbo-11818-has-robust-anti-tumor-activity-in-kras-mutant-preclinical-models-at-the-aacr-annual-meeting-2026</guid>
      <pubDate>Wed, 22 Apr 2026 20:05:00 GMT</pubDate>
      <description>BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines BBO-11818 demonstrates robust anti-tumor activity as monotherapy and in combination across KRAS-mutant tumor models Updated Phase 1 clinical data are expected in the second half of 2026 SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT</description>
    </item>
    <item>
      <title>BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-presents-preclinical-data-showing-raspi3ka-breaker-bbo-10203-inhibits-pi3kaakt-signaling-in-her2amp-models-at-the-aacr-annual-meeting-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-presents-preclinical-data-showing-raspi3ka-breaker-bbo-10203-inhibits-pi3kaakt-signaling-in-her2amp-models-at-the-aacr-annual-meeting-2026</guid>
      <pubDate>Tue, 21 Apr 2026 21:30:00 GMT</pubDate>
      <description>BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia BBO-10203 displays strong in vivo combination effects with HER2 inhibitors tucatinib or trastuzumab in HER2AMP models Updated clinical data are expected in the second half of 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasda</description>
    </item>
    <item>
      <title>BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-granted-us-fda-fast-track-designation-for-bbo-11818-for-the-treatment-of-adult-patients-with-advanced-kras-mutant-pancreatic-ductal-adenocarcinoma</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-granted-us-fda-fast-track-designation-for-bbo-11818-for-the-treatment-of-adult-patients-with-advanced-kras-mutant-pancreatic-ductal-adenocarcinoma</guid>
      <pubDate>Mon, 20 Apr 2026 20:06:00 GMT</pubDate>
      <description>BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected in the second half of 2026 SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the U.S. Food and Drug Administration (FDA)</description>
    </item>
    <item>
      <title>BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bridgebio-oncology-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bridgebio-oncology-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
      <pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage</description>
    </item>
    <item>
      <title>BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-multiple-presentations-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-multiple-presentations-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026</guid>
      <pubDate>Wed, 18 Mar 2026 20:05:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 being held on April 17-22, 2026, in San Diego, California. The abstracts released today can be found on the AACR website here. Details on the presentations are as follows: Title:</description>
    </item>
    <item>
      <title>BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-publication-in-cancer-discovery-highlighting-preclinical-data-demonstrating-bbo-11818-is-a-potent-and-selective-pankras-inhibitor-107</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-publication-in-cancer-discovery-highlighting-preclinical-data-demonstrating-bbo-11818-is-a-potent-and-selective-pankras-inhibitor-107</guid>
      <pubDate>Fri, 06 Mar 2026 15:07:00 GMT</pubDate>
      <description>BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical models, including KRASG12D and KRASG12V BBO-11818 showed significant tumor growth inhibition across multiple tumor types in preclinical models and demonstrated enhanced efficacy in combination with other anti-tumor agents, including BBO-10203, BBOT’s selective RAS:PI3Kα breaker Prelim</description>
    </item>
    <item>
      <title>BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-reports-fourth-quarter-and-full-year-2025-financial-results-and-update-on-corporate-progress-63</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-reports-fourth-quarter-and-full-year-2025-financial-results-and-update-on-corporate-progress-63</guid>
      <pubDate>Thu, 05 Mar 2026 21:05:00 GMT</pubDate>
      <description>BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520’s differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response in</description>
    </item>
    <item>
      <title>BBOT to Participate in Upcoming Investor Healthcare Conferences</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-to-participate-in-upcoming-investor-healthcare-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-to-participate-in-upcoming-investor-healthcare-conferences</guid>
      <pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in the upcoming months. Details of the company’s participation are as follows: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation: Wednesday, February 25, 2026, at 10:40 a.m. E</description>
    </item>
    <item>
      <title>BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-new-clinical-data-advancing-its-portfolio-of-three-innovative-and-differentiated-ras-and-pi3ka-pipeline-programs</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-new-clinical-data-advancing-its-portfolio-of-three-innovative-and-differentiated-ras-and-pi3ka-pipeline-programs</guid>
      <pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
      <description>BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month</description>
    </item>
    <item>
      <title>BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</guid>
      <pubDate>Tue, 16 Dec 2025 21:05:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. PT. A live webcast of the presentation will be accessible on the “Events” page of the BBOT website at https://in</description>
    </item>
    <item>
      <title>BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-reports-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage</description>
    </item>
    <item>
      <title>BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-late-breaking-preclinical-data-on-bbo-10203-a-first-in-class-raspi3ka-breaker-at-the-san-antonio-breast-cancer-symposium-sabcs</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-late-breaking-preclinical-data-on-bbo-10203-a-first-in-class-raspi3ka-breaker-at-the-san-antonio-breast-cancer-symposium-sabcs</guid>
      <pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
      <description>Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing</description>
    </item>
    <item>
      <title>BBOT to Participate in Upcoming December Investor Healthcare Conferences</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-to-participate-in-upcoming-december-investor-healthcare-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-to-participate-in-upcoming-december-investor-healthcare-conferences</guid>
      <pubDate>Tue, 18 Nov 2025 21:05:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in December. Details of the company’s participation are as follows: Piper Sandler 37th Annual Healthcare ConferencePresentation: Tuesday, December 2, at 2:00 p.m. ET 8th Annual Evercore Healthcare</description>
    </item>
    <item>
      <title>BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-reports-third-quarter-2025-financial-results-and-update-on-corporate-progress</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-reports-third-quarter-2025-financial-results-and-update-on-corporate-progress</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio</description>
    </item>
    <item>
      <title>BBOT to Participate in the Jefferies Global Healthcare Conference in London</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-to-participate-in-the-jefferies-global-healthcare-conference-in-london</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-to-participate-in-the-jefferies-global-healthcare-conference-in-london</guid>
      <pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the Jefferies Global Healthcare Conference on Monday, November 17, at 2:30 p.m. GMT. A live webcast of the presentation will be accessible on the “Events” page of the BBOT website at https://investors.bbo</description>
    </item>
    <item>
      <title>BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-poster-presentations-at-the-san-antonio-breast-cancer-symposium-sabcs</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-poster-presentations-at-the-san-antonio-breast-cancer-symposium-sabcs</guid>
      <pubDate>Thu, 30 Oct 2025 21:45:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced two poster presentations featuring BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, at the San Antonio Breast Cancer Symposium (SABCS) being held December 9-12, 2025, in San Antonio, Texas. The abstracts released today can be fou</description>
    </item>
    <item>
      <title>Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/preclinical-data-presented-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-support-potential-of-bbo-10203-a-first-in-class-raspi3ka-breaker-that-inhibits-kras-mutant-tumor-growth-without-inducing-hyperglycemia</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/preclinical-data-presented-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-support-potential-of-bbo-10203-a-first-in-class-raspi3ka-breaker-that-inhibits-kras-mutant-tumor-growth-without-inducing-hyperglycemia</guid>
      <pubDate>Sat, 25 Oct 2025 16:30:00 GMT</pubDate>
      <description>Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monotherapy activity, as well as combination activity with BBOT’s KRASG12C ON/OFF inhibitor, BBO-8520, and panKRAS inhibitor, BBO-11818, was observed at well-tolerated dose levels in a panel of KRAS-mutant modelsThe combination of a KRAS inhibitor with a PI3Kα pathway inhibitor may maximize the response rate and reduce the development o</description>
    </item>
    <item>
      <title>BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-presents-preclinical-data-demonstrating-potential-of-bbo-11818-as-a-potent-pankras-inhibitor-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-presents-preclinical-data-demonstrating-potential-of-bbo-11818-as-a-potent-pankras-inhibitor-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics</guid>
      <pubDate>Thu, 23 Oct 2025 20:05:00 GMT</pubDate>
      <description>Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRASG12D and KRASG12V cell-derived xenograft (CDX) modelsBBO-11818’s selectivity for KRAS demonstrated by its &gt;1000-fold lower potency against NRAS, HRAS, and BRAF-mutant cell linesEfficacy of the combination with BBOT’s RAS:PI3K⍺ breaker, BBO-10203, is driven by a robust decrease in tumor cell proliferation and increase in apoptosis; combination benefit a</description>
    </item>
    <item>
      <title>BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-poster-presentations-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-announces-poster-presentations-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics</guid>
      <pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage</description>
    </item>
    <item>
      <title>BBOT to Participate in Upcoming September Investor Healthcare Conferences</title>
      <link>https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-to-participate-in-upcoming-september-investor-healthcare-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/bridgebio-oncology-therapeutics-inc/news/bbot-to-participate-in-upcoming-september-investor-healthcare-conferences</guid>
      <pubDate>Wed, 20 Aug 2025 12:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September. Details of the company’s participation are as follows: Cantor Global Healthcare Conference Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in</description>
    </item>
  </channel>
</rss>